CEO, Botanix Pharmaceuticals
Matt Callahan is a life sciences entrepreneur and CEO with a track record of building and exiting life sciences companies in pain, oncology, dermatology and regenerative medicine. Matt was the founding CEO of iCeutica and a co-inventor of some of the technologies that comprise the SoluMatrix™ Fine Particle Technology that has been utilized in 4 FDA approved products. He has 20 years legal, life sciences, IP and investment management experience and was also a co-founder of Dimerix Bioscience, Botanix Pharmaceuticals, Mirata Pharmaceuticals, Respirion Pharmaceuticals and Orthocell.
Mr Callahan has worked as an investment director for two venture capital firms investing in life sciences, IT&T and industrial technologies and was also previously General Counsel with a listed patent licensing company, where he was responsible for generating more than $120M in revenues from both carrot and stick licensing programs. Following a career with a large multinational law firm, Mr Callahan also co-founded 2 software startup companies in the health IT space.
Mr Callahan holds a Bachelor of Laws with honors and Masters of Business Administration, from the University of Western Australia and has worked extensively in Australia, Germany, the UK and the USA.